Literature DB >> 23322777

Mechanisms by which von Willebrand disease mutations destabilize the A2 domain.

Amy J Xu1, Timothy A Springer.   

Abstract

von Willebrand Factor (VWF) is an ultralong, concatameric, and adhesive glycoprotein. On short time scales, adhesiveness for platelets is activated by elongation of VWF by altered hydrodynamics at sites of hemostasis. Over longer time scales, the length of VWF is regulated by ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13), cleavage by which in the VWF A2 domain is dependent on elongational force. Patients with von Willebrand disease type 2A present with increased bleeding due to mutations within the VWF A2 domain that enhance cleavage. We tested using temperature and force the hypothesis that von Willebrand disease mutations disrupt A2 force sensing by destabilizing the folded state. Mutations R1597W, M1528V, and E1638K reduced A2 thermal stability by 10-18 °C. M1528V and E1638K showed a marked further decrease in stability upon calcium removal. In contrast, R1597W, which resides within the A2 calcium-binding loop, exhibited similar stability in the presence and absence of calcium. Using single molecule optical tweezers and R1597W, we measured the force dependence of unfolding and refolding kinetics. In the presence of calcium, the R1597W mutation slowed the rate of refolding but had no effect on unfolding. The three mutations highlight the calcium-binding loop (R1597W), the hydrophobic core around the vicinal disulfide (M1528V), and hydrogen bonds to the α4-less loop (E1638K), as structural features critically important to the function of A2 as a force sensor in regulating thrombogenic activity in the vasculature.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322777      PMCID: PMC3585066          DOI: 10.1074/jbc.M112.422618

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Extending CD spectra of proteins to 168 nm improves the analysis for secondary structures.

Authors:  A Toumadje; S W Alcorn; W C Johnson
Journal:  Anal Biochem       Date:  1992-02-01       Impact factor: 3.365

2.  Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.

Authors:  Wolf Achim Hassenpflug; Ulrich Budde; Tobias Obser; Dorothea Angerhaus; Elke Drewke; Sonja Schneppenheim; Reinhard Schneppenheim
Journal:  Blood       Date:  2005-12-01       Impact factor: 22.113

3.  Dynamic strength of molecular adhesion bonds.

Authors:  E Evans; K Ritchie
Journal:  Biophys J       Date:  1997-04       Impact factor: 4.033

Review 4.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.

Authors:  J E Sadler; U Budde; J C J Eikenboom; E J Favaloro; F G H Hill; L Holmberg; J Ingerslev; C A Lee; D Lillicrap; P M Mannucci; C Mazurier; D Meyer; W L Nichols; M Nishino; I R Peake; F Rodeghiero; R Schneppenheim; Z M Ruggeri; A Srivastava; R R Montgomery; A B Federici
Journal:  J Thromb Haemost       Date:  2006-08-02       Impact factor: 5.824

Review 5.  New concepts in von Willebrand disease.

Authors:  J Evan Sadler
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

6.  Calcium stabilizes the von Willebrand factor A2 domain by promoting refolding.

Authors:  Amy J Xu; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-22       Impact factor: 11.205

7.  Influence of mutations and size of multimers in type II von Willebrand disease upon the function of von Willebrand factor.

Authors:  O Christophe; A S Ribba; D Baruch; B Obert; C Rouault; K Niinomi; G Piétu; D Meyer; J P Girma
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

8.  Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations.

Authors:  S E Lyons; M E Bruck; E J Bowie; D Ginsburg
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

9.  Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.

Authors:  L W Hoyer; J R Shainoff
Journal:  Blood       Date:  1980-06       Impact factor: 22.113

10.  Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.

Authors:  A S Ribba; J Voorberg; D Meyer; H Pannekoek; G Pietu
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

View more
  13 in total

1.  Internal tension in a collapsed polymer under shear flow and the connection to enzymatic cleavage of von Willebrand factor.

Authors:  Matthias Radtke; Svenja Lippok; Joachim O Rädler; Roland R Netz
Journal:  Eur Phys J E Soft Matter       Date:  2016-03-22       Impact factor: 1.890

Review 2.  von Willebrand factor, Jedi knight of the bloodstream.

Authors:  Timothy A Springer
Journal:  Blood       Date:  2014-06-13       Impact factor: 22.113

Review 3.  Molecular mechanisms of disease-causing missense mutations.

Authors:  Shannon Stefl; Hafumi Nishi; Marharyta Petukh; Anna R Panchenko; Emil Alexov
Journal:  J Mol Biol       Date:  2013-07-16       Impact factor: 5.469

4.  N-linked glycan stabilization of the VWF A2 domain.

Authors:  Christopher J Lynch; David A Lane
Journal:  Blood       Date:  2016-01-14       Impact factor: 22.113

5.  Epsin-Dependent Ligand Endocytosis Activates Notch by Force.

Authors:  Paul D Langridge; Gary Struhl
Journal:  Cell       Date:  2017-11-30       Impact factor: 41.582

6.  Massively parallel enzyme kinetics reveals the substrate recognition landscape of the metalloprotease ADAMTS13.

Authors:  Colin A Kretz; Manhong Dai; Onuralp Soylemez; Andrew Yee; Karl C Desch; David Siemieniak; Kärt Tomberg; Fyodor A Kondrashov; Fan Meng; David Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

7.  Probing ADAMTS13 substrate specificity using phage display.

Authors:  Karl C Desch; Colin Kretz; Andrew Yee; Robert Gildersleeve; Kristin Metzger; Nidhi Agrawal; Jane Cheng; David Ginsburg
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

8.  A novel monoclonal antibody against the von Willebrand Factor A2 domain reduces its cleavage by ADAMTS13.

Authors:  Lulu Zhang; Jian Su; Fei Shen; Zhenni Ma; Yiming Zhao; Lijun Xia; Changgeng Ruan
Journal:  J Hematol Oncol       Date:  2017-02-06       Impact factor: 17.388

9.  A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct.

Authors:  Christopher J Lynch; Adam D Cawte; Carolyn M Millar; David Rueda; David A Lane
Journal:  PLoS One       Date:  2017-11-29       Impact factor: 3.240

10.  Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF.

Authors:  Christopher J Lynch; David A Lane; Brenda M Luken
Journal:  Blood       Date:  2014-02-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.